Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
APLS Stock Chart & Stats
$29.78
-$1.37(-3.96%)
At close: 4:00 PM EST
$29.78
-$1.37(-3.96%)
Day’s Range― - ―
52-Week Range$16.10 - $35.72
Previous CloseN/A
Volume215.04K
Average Volume (3M)2.34M
Market Cap
$3.56B
Enterprise Value$2.28B
Total Cash (Recent Filing)$371.47M
Total Debt (Recent Filing)$469.77M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Oct 30, 2025EPS Estimate
1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding126,289,910
10 Day Avg. Volume2,253,310
30 Day Avg. Volume2,341,490
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)17.30
Price to Sales (P/S)5.06
P/FCF Ratio-44.79
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda-12.78
Forecast
1Y Price Target
$36.06Price Target Upside21.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageEmpaveli is the only treatment that offers greater efficacy with proteinuria reduction, eGFR, and C3 deposition, which are the goals that clinicians have long sought to accomplish.
Market PotentialLaunch in IC-MPGN and C3G have significant potential and could ultimately become a blockbuster.
Product EffectivenessEmpaveli maintains significant proteinuria reduction regardless of immunosuppressant use or baseline proteinuria levels.
Bears Say
Financial Performance RisksAPLS has been downgraded from Neutral to Sell due to concerns about its future performance.
Market Adoption ConcernsEmpaveli’s usage could be limited by the fragmented market and potential payor access issues.
Regulatory ChallengesKey risks include regulatory approval, since products are not approved for all the indications the company is pursuing.
Apellis Pharmaceuticals News
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $16.10 and its highest was $35.72 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Apellis Pharmaceuticals Inc’s market cap is $3.56B.
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Oct 30, 2025 which is tomorrow.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Jul 31, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.465 by $0.135.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is 1.58.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 126,289,910 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.465. Following the earnings report the stock price went up 17.579%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in APLS
Apellis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.06 (21.09% Upside)
$36.06 (21.09% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 336.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.61%
12-Months-Change
Fundamentals
Return on Equity
-108.49%
Trailing 12-Months
Asset Growth
-9.19%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies to treat serious diseases. The company specializes in complement immunotherapy, targeting the complement system to provide solutions for conditions such as geographic atrophy and other rare diseases. Apellis is primarily engaged in the research, development, and commercialization of its core product, pegcetacoplan, which is designed to address unmet medical needs in the ophthalmology and hematology sectors.
APLS Company Deck
APLS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive trajectory for Apellis with significant achievements such as FDA approval for EMPAVELI's expanded label, continued market leadership of SYFOVRE, and strong financial positioning. However, challenges such as high free goods usage affecting revenue and ongoing funding shortages for patient assistance programs present areas of concern.View all APLS earnings summariesAPLS Stock 12 Month Forecast
Average Price Target
$36.06
▲(21.09% Upside)
Technical Analysis
Zai Lab
―
Crinetics Pharmaceuticals
―
Akero Therapeutics
―
Mirum Pharmaceuticals
―
MoonLake Immunotherapeutics
―
Ownership Overview
3.18% Insiders
17.84% Mutual Funds
0.04% Other Institutional Investors
63.26% Public Companies and
Individual Investors